These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 35567808)
21. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry. Sebba A; Bingham CO; Bykerk VP; Fiore S; Ford K; Janak JC; Pappas DA; Blachley T; Dave SS; Kremer JM; Yu M; Choy E Clin Rheumatol; 2023 Aug; 42(8):2037-2051. PubMed ID: 37060528 [TBL] [Abstract][Full Text] [Related]
22. Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. Jin Y; Kang EH; Brill G; Desai RJ; Kim SC J Rheumatol; 2018 Aug; 45(9):1240-1248. PubMed ID: 29764964 [TBL] [Abstract][Full Text] [Related]
23. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785 [TBL] [Abstract][Full Text] [Related]
24. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829 [TBL] [Abstract][Full Text] [Related]
25. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Desai RJ; Pawar A; Weinblatt ME; Kim SC Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833 [TBL] [Abstract][Full Text] [Related]
26. Increased risk of herpes zoster with tofacitinib treatment in Korean patients with rheumatoid arthritis: a single-center prospective study. Song YJ; Cho SK; Kim H; Kim HW; Nam E; Jeon JY; Yoo HJ; Choi CB; Kim TH; Jun JB; Bae SC; Yoo DH; Sung YK Sci Rep; 2023 May; 13(1):7877. PubMed ID: 37188765 [TBL] [Abstract][Full Text] [Related]
27. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors. Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419 [TBL] [Abstract][Full Text] [Related]
28. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register. Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. Shin K; Baek HJ; Kang YM; Cha HS; Kang SW; Park SH; Jun JB; Lee YJ; Choi IA; Song YW Int J Rheum Dis; 2019 Jun; 22(6):1115-1122. PubMed ID: 30861334 [TBL] [Abstract][Full Text] [Related]
30. Switching from TNFα inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNFα inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial. Jung SY; Koh JH; Kim KJ; Park YW; Yang HI; Choi SJ; Lee J; Choi CB; Kim WU Arthritis Res Ther; 2021 Jul; 23(1):182. PubMed ID: 34233727 [TBL] [Abstract][Full Text] [Related]
31. Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. Desai RJ; Solomon DH; Schneeweiss S; Danaei G; Liao KP; Kim SC Epidemiology; 2016 May; 27(3):414-22. PubMed ID: 26808597 [TBL] [Abstract][Full Text] [Related]
32. Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders. Hoshida Y; Tsujii A; Ohshima S; Saeki Y; Yagita M; Miyamura T; Katayama M; Kawasaki T; Hiramatsu Y; Oshima H; Murayama T; Higa S; Kuraoka K; Hirano F; Ichikawa K; Kurosawa M; Suzuki H; Chiba N; Sugiyama T; Minami Y; Niino H; Ihata A; Saito I; Mitsuo A; Maejima T; Kawashima A; Tsutani H; Takahi K; Kasai T; Shinno Y; Tachiyama Y; Teramoto N; Taguchi K; Naito S; Yoshizawa S; Ito M; Suenaga Y; Mori S; Nagakura S; Yoshikawa N; Nomoto M; Ueda A; Nagaoka S; Tsuura Y; Setoguchi K; Sugii S; Abe A; Sugaya T; Sugahara H; Fujita S; Kunugiza Y; Iizuka N; Yoshihara R; Yabe H; Fujisaki T; Morii E; Takeshita M; Sato M; Saito K; Matsui K; Tomita Y; Furukawa H; Tohma S Arthritis Rheumatol; 2024 Jun; 76(6):869-881. PubMed ID: 38272827 [TBL] [Abstract][Full Text] [Related]
33. Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study. Song YJ; Cho SK; You SH; Kim JY; Kim H; Jung SY; Sung YK RMD Open; 2022 Dec; 8(2):. PubMed ID: 36549855 [TBL] [Abstract][Full Text] [Related]
34. Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil). Bredemeier M; Ranza R; Kakehasi AM; Ranzolin A; da Silveira IG; Ribeiro ACM; Titton DC; Hayata ALS; Carvalho HMS; Kahlow BS; Fernandes V; Louzada P; Bértolo MB; Duarte ÂLBP; Macieira JC; Miranda JRS; Pinheiro GRC; Teodoro RB; Pinheiro MM; Valim V; Pereira IA; Sauma MFLC; de Castro GRW; da Rocha LF; Studart SAS; Gazzeta MO; da Silveira LG; Lupo CM; Laurindo IMM J Rheumatol; 2021 Oct; 48(10):1519-1527. PubMed ID: 33934077 [TBL] [Abstract][Full Text] [Related]
35. Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study. Harada S; Sakai R; Hirano F; Miyasaka N; Harigai M; J Rheumatol; 2017 Jul; 44(7):988-995. PubMed ID: 28412701 [TBL] [Abstract][Full Text] [Related]
36. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs. Zhao J; Ye X; Zhang Z Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975 [TBL] [Abstract][Full Text] [Related]
37. The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Martínez-Feito A; Plasencia-Rodríguez C; Navarro-Compán V; Hernández-Breijo B; González MÁ; Monjo I; Nuño L; Nozal P; Pascual-Salcedo D; Balsa A Clin Rheumatol; 2019 Mar; 38(3):949-954. PubMed ID: 30402698 [TBL] [Abstract][Full Text] [Related]
38. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801 [TBL] [Abstract][Full Text] [Related]
39. Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis. Bower H; Frisell T; di Giuseppe D; Delcoigne B; Askling J RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996125 [TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive. Harrold LR; Wittstock K; Kelly S; Han X; Zhuo J; Schrader A; Middaugh N; Moore PC; Khaychuk V Adv Rheumatol; 2024 Jan; 64(1):10. PubMed ID: 38243281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]